Therapy treats refractory chronic immune thrombocytopenia and is available across UK.
Grifols has announced that its treatment for adults with chronic immune thrombocytopenia (ITP), Tavlesse – also known as fostamatinib – is now recommended by the National Institute for Health and Care Excellence (NICE).
With NICE’s recommendation, specifically for those patients who have previously had a thrombopoietin receptor agonist TPO-RA, or for whom a TPO-RA is unsuitable, Tavlesse can now be accessed and reimbursed by the NHS across the UK. Last year, the Scottish Medicines Consortium also advised acceptance of the treatment…
